Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A3921145 Long-Term Open-Label Follow-Up of Tofacitinib in JIA
2023-509651-14-00Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 3, open-label, single-arm trial of tofacitinib in juvenile idiopathic arthritis (JIA), systemic juvenile idiopathic arthritis (SJIA) and juvenile idiopathic arthritis, enthesitis-related (JIA-ERA), sponsored by Pfizer. Primary endpoint: Safety and growth/physical development. Started Jun 2024; status: completed.
02
Drugs
03
Conditions
juvenile idiopathic arthritis (JIA)systemic juvenile idiopathic arthritis (SJIA)juvenile idiopathic arthritis, enthesitis-related (JIA-ERA)
Beyond the preview
Go deeper on 2023-509651-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509651-14-00.